Lifecycle Pharma gets good results with LCP-Tacro

11/7/2007 | Forbes

LCP-Tacro, a potential drug treatment designed to prevent organ rejection after transplant surgery, was successful in Phase I clinical trials, its maker, Lifecycle Pharma AS, said. In the study, the treatment compared favorably to the transplant treatment Advagraf.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN